GFS Advisors’s Bristol-Myers Squibb BMY Stock Holding History

GFS Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.64M	Buy	26,975 +165	+0.6%	+$9.62K	0.21%	78
2025 Q4	$1.45M	Buy	+26,810	New	+$1.29M	0.17%	88
2023 Q4	–	Sell	-12,850	Closed	-$746K	–	153
2023 Q3	$746K	Buy	+12,850	New	+$787K	0.12%	108
2020 Q2	–	Sell	-6,030	Closed	-$336K	–	120
2020 Q1	$336K	Sell	6,030 -100	-2%	-$6.11K	0.1%	92
2019 Q4	$393K	Buy	6,130 +100	+2%	+$5.73K	0.1%	100
2019 Q3	$306K	Hold	6,030	–	–	0.09%	104
2019 Q2	$273K	Hold	6,030	–	–	0.08%	106
2019 Q1	$288K	Sell	6,030 -210	-3%	-$10.5K	0.09%	99
2018 Q4	$324K	Buy	6,240 +2,330	+60%	+$125K	0.09%	96
2018 Q3	$243K	Hold	3,910	–	–	0.06%	117
2018 Q2	$216K	Hold	3,910	–	–	0.04%	137
2018 Q1	$259K	Sell	3,910 -13	-0.3%	-$836	0.05%	128
2017 Q4	$240K	Sell	3,923 -888	-18%	-$55.5K	0.05%	131
2017 Q3	$307K	Sell	4,811 -223	-4%	-$13K	0.07%	128
2017 Q2	$280K	Hold	5,034	–	–	0.06%	134
2017 Q1	$274K	Buy	+5,034	New	+$276K	0.06%	132

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GFS Advisors's BMY Position: Q1 2026 in Review

GFS Advisors increased its Bristol-Myers Squibb (BMY) stake by 0.62% in Q1 2026, buying an estimated $9.62K and bringing the position to 26,975 shares worth $1.64M. The position accounts for 0.21% of the portfolio, ranked #78.

GFS Advisors first reported a position in BMY in Q1 2017 and has held it in 16 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

GFS Advisors held 26,975 shares of Bristol-Myers Squibb worth $1.64M as of Q1 2026.
GFS Advisors bought 165 Bristol-Myers Squibb shares in Q1 2026, an estimated $9.62K.
Bristol-Myers Squibb made up 0.21% of GFS Advisors's portfolio in Q1 2026, its #78 holding.
GFS Advisors first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 16 quarters since.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on GFS Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.